This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Song, P. Articles by Spindel, E. R. Search for Related Content PubMed PubMed Citation Articles by Song, P. Articles by Spindel, E. R.

Activated Cholinergic Signaling Provides a Target in Squamous Cell Lung Carcinoma

¹ Division of Neuroscience, Oregon National Primate Research Center, Oregon Health and Sciences University, Beaverton, Oregon; ² Department of Neuroscience, University of Pennsylvania Medical School, Philadelphia, Pennsylvania; ³ Department of Behavioral Neuroscience, Oregon Health and Sciences University, Portland, Oregon; and ⁴ Novartis Institutes for Biomedical Research, Cambridge, Massachusetts

Requests for reprints: Eliot R. Spindel, Division of Neuroscience, Oregon National Primate Research Center, Oregon Health and Sciences University, 505 Northwest 185th Avenue, Beaverton, OR 97006. Phone: 503-690-5512; Fax: 503-690-5384; E-mail: spindele{at}ohsu.edu.

Key Words: lung cancer • nicotine • nicotinic receptors • muscarinic receptors • acetylcholine

The binding of exogenous nicotine to nicotinic acetylcholine (ACh) receptors (nAChR) and the binding of endogenous ACh to both nAChR and muscarinic ACh receptors (mAChR) stimulate growth of both small cell and non–small cell lung carcinomas. Understanding how cholinergic signaling is up-regulated in lung cancer may suggest new therapeutic approaches. Analysis of 28 squamous cell lung carcinomas (SCC) showed increased levels of 5 and β3 nAChR mRNA and increased levels of ACh associated with increased levels of choline acetyltransferase mRNA and decreased cholinesterase mRNAs. Lynx1, an allosteric inhibitor of nAChR activity, was also decreased in SCC. Thus, cholinergic signaling is broadly increased in SCC caused by increased levels of receptors, increased levels of ligands, and decreased levels of receptor inhibitors. Partially explaining the cholinergic up-regulation seen in SCC, incubation of the H520 SCC cell line with nicotine increased levels of ACh secretion, increased expression of nAChR, and, as measured by electrophysiologic recording, increased activity of the expressed nAChR. Consistent with these effects, nicotine stimulated proliferation of H520 cells. One approach to blocking proliferative effects of nicotine and ACh on growth of lung cancers may be through M3 mAChR antagonists, which can limit the activation of mitogen-activated protein kinase that is caused by both nicotinic and muscarinic signaling. This was tested with the M3-selective muscarinic antagonist darifenacin. Darifenacin blocked nicotine-stimulated H520 growth in vitro and also blocked H520 growth in nude mice in vivo. Thus, cholinergic signaling is broadly up-regulated in SCC and blocking cholinergic signaling can limit basal and nicotine-stimulated growth of SCC. [Cancer Res 2008;68(12):4693–700]

This article has been cited by other articles:

				E. H Lips, V. Gaborieau, J. D McKay, A. Chabrier, R. J Hung, P. Boffetta, M. Hashibe, D. Zaridze, N. Szeszenia-Dabrowska, J. Lissowska, et al. Association between a 15q25 gene variant, smoking quantity and tobacco-related cancers among 17 000 individuals Int. J. Epidemiol., September 23, 2009; (2009) dyp288v1. [Abstract] [Full Text] [PDF]

				E. R. Spindel Is Nicotine the Estrogen of Lung Cancer? Am. J. Respir. Crit. Care Med., June 15, 2009; 179(12): 1081 - 1082. [Full Text] [PDF]

				E. Brambilla and A. Gazdar Pathogenesis of lung cancer signalling pathways: roadmap for therapies Eur. Respir. J., June 1, 2009; 33(6): 1485 - 1497. [Abstract] [Full Text] [PDF]

				S. Dubey and C. A. Powell Update in Lung Cancer 2008 Am. J. Respir. Crit. Care Med., May 15, 2009; 179(10): 860 - 868. [Full Text] [PDF]

				F. S. Falvella, A. Galvan, E. Frullanti, M. Spinola, E. Calabro, A. Carbone, M. Incarbone, L. Santambrogio, U. Pastorino, and T. A. Dragani Transcription Deregulation at the 15q25 Locus in Association with Lung Adenocarcinoma Risk Clin. Cancer Res., March 1, 2009; 15(5): 1837 - 1842. [Abstract] [Full Text] [PDF]

				N. Shah, S. Khurana, K. Cheng, and J.-P. Raufman Muscarinic receptors and ligands in cancer Am J Physiol Cell Physiol, February 1, 2009; 296(2): C221 - C232. [Abstract] [Full Text] [PDF]

				M. R. Spitz, C. I. Amos, Q. Dong, J. Lin, and X. Wu The CHRNA5-A3 Region on Chromosome 15q24-25.1 Is a Risk Factor Both for Nicotine Dependence and for Lung Cancer J Natl Cancer Inst, November 5, 2008; 100(21): 1552 - 1556. [Abstract] [Full Text] [PDF]